Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline Nasal Spray for Dry Eye Disease Phase 3 China
CTR20221182Phase 3Completed
- Sponsor
- Oyster Point Pharma
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing varenicline nasal spray with placebo nasal spray (2 arms). Primary endpoint: Proportion of subjects with STS increase ≥10 mm from baseline at Day 28. Started May 2022; status: completed.
02
Drugs
varenicline
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20221182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221182.